Read our latest collection: Regaining Our Balance: How to Right the Wrongs of Globalization
Sign up to receive The Commons posts in your inbox.
Government, Not Markets Can Best Pick Winners
Finding a Manufacturer (Image Courtesy Wikimedia https://goo.gl/images/ozWa0Q)
China’s economic rise and the damage inflicted on U.S. industry has been a wakeup call to many U.S. policymakers. But most conventional economists continue to hold firm to their ideological notion that only the market can respond, and that any more proactive government action, particularly focused on key sectors or technologies, is doomed to fail. For many, the only choice is between China’s command-and-control playbook and the market, albeit one perhaps supported by a bit more spending on education and research. This is ideological framing of the first order, grounded in neither logic nor research. The reality is that government is best positioned to “pick winners.”
Innovation-based industries are subject to a significant number of market failures, including externalities, network failures, system interdependencies, and the public-goods nature of technology platforms. For example, companies investing in research, on average, capture less than half the returns from that research, even with robust intellectual property protection. The other benefits go to consumers and competitors. This means, absent policies such as an R&D tax credit or pre-competitive R&D grants, companies will underinvest in research relative to the level that would maximize economy-wide returns.
Moreover, the divergence between public and private returns from investments in innovation means that it is actually government that can best “pick winners.”Consider two technologies: one that provides business with a rate of return (ROR) of 20 percent and no spillovers to society, for a societal ROR of 20 percent; and another that provides business with a 10 percent return and spillovers that generate a societal ROR of 30 percent. Market forces will target capital to the former and business will undervest in the latter, thereby reducing overall growth. This does not of course mean government ownership of the means of production or heavy-handed government direction. Can we stop raising this canard? Nor does it mean that forward-looking corporate management with companies investing for long-term profit maximization are not critical to American success. Of course they are. But it does mean that absent robust government industrial and technology policies, that America will underperform our competitors, especially nations like China which is pouring hundreds of billions of dollars in support advanced industries.
This does not mean, as the skeptics will continue to cry, moving to “Soviet Gosplan” or “crony capitalism.” No, as the essays in “Rebooting the American System” show, the U.S. government has a long and proud tradition of “picking winners.” And multiple agencies today, including DOD’s DARPA, DOE’s ARPA-E and NIH, successfully identify and support technological innovations critical to our nation’s future. It’s time to recognize that and extend that support beyond national missions of defense, energy and health and make commercial competitive success against China a core national mission. If we don’t we can ensure that the market will adapt, leading to even more waste paper and soybean exports to China.Return to the Commons
Markets do not naturally tend toward “equilibrium.” They are wrecking balls if not properly harnessed. High levels of debt, which can be a source of strength (by enabling higher levels of investment than could be financed otherwise), can also be a source of vulnerability if the government fails to coordinate investment, curb excess capacity, and […]
Operation Warp Speed (OWS) was a nearly miraculous COVID-19 vaccine success story. What is less widely recognized is that it has also unlocked a biotech revolution. The mRNA technologies that OWS helped bring to market have numerous potential applications, ranging from cancer treatments to hormone replacement therapies to radical new ways to treat infectious disease. […]